Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
708 (USA) · Dr. Kim
consented 2013-08-23
AEs
2
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Mild APPLICATION SITE ERYTHEMA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-02-15 (study day 177.0); relationship: PROBABLE
mild
assessed
Mild HEADACHE — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-01-29 (study day 160.0); relationship: POSSIBLE
Data queries
No data queries.